Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

New Heights in Patient Care: Elevating Science in Treating Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis

New Heights in Patient Care: Elevating Science in Treating Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis

Fast-paced and focused on emerging science and treatment techniques, New Heights in Patient Care was an interactive activity designed to sharpen participants’ understanding of psoriasis, psoriatic arthritis (PsA), and atopic dermatitis (AD) and equip them with forward-thinking, patient-centered communication strategies. Through a combination of medical animation, TED Talks-style presentations, a clinical case study, and a discussion of patient-provider shared decision making, learners explored disease pathophysiology, mechanisms of action (MOAs) of targeted therapies, evidence-based treatment recommendations, and use of decision aids.

  • Neil Korman, MD, PhD
    Director, Clinical Trials Unit
    Clinical Director, Murdough Family Center for Psoriasis
    Professor, Dermatology
    University Hospitals Cleveland Medical Center
    Case Western Reserve University School of Medicine
    Cleveland, Ohio

  • Richard Martin, MD, MA

    Richard Martin, MD, MA
    Professor of Medicine and Rheumatology,
    Michigan State University College of Human Medicine
    East Lansing, Michigan

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    • Marianna Shershneva, MD, PhD
    • Jessica Porucznik

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Neil Korman, MD, PhD
    • Advisor: AbbVie, Celgene, Lilly, Janssen, Novartis, Regeneron, UCB, Valeant
    • Investigator: AbbVie, Chugai, Dermira, Leo, Lilly, Janssen, Merck, Pfizer, Prothena, Regeneron, UCB
    • Speaker: AbbVie, Celgene, Janssen, Lilly, Novartis, Regeneron
    • Consultant: Novartis, Pfizer
  • Presenter: Richard Martin, MD, MA
    • Contracted research: AbbVie, Amgen, AstraZeneca, Cytori, Lilly
  • Planner: Lakshi Aldredge, MSN, ANP-BC, DCNP
    • Consultant and speaker: AbbVie, Celgene, Lilly, Novartis, Sanofi, Sun Pharma, Regeneron
  • Planner: April W. Armstrong MD, MPH
    • Consultant: AbbVie, Bristol-Myers Squibb, Dermavant, Janssen, LEO Pharma, Lilly, Modernizing Medicine, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Science 37
    • Researcher: AbbVie, Bristol-Myers Squibb, Dermira, Janssen, Kyowa Hakko Kirin, LEO Pharma, Lilly, Novartis, Regeneron, Sanofi Genzyme, UCB

As a result of participation in this educational activity, participants should increase their ability to:

  • Describe

    Describe current models explaining and comparing pathophysiology of psoriasis, psoriatic arthritis, and atopic dermatitis

  • identify

    Identify mechanisms of action and effectiveness of existing and emerging targeted treatments for psoriasis, psoriatic arthritis, and atopic dermatitis

  • Recognize

    Recognize key clinical manifestations of psoriatic arthritis

  • Use patient-reported and provider-reported outcome measures to guide treatment decisions and quantify treatment response in patients with psoriatic arthritis

  • Involve patients with psoriatic disease or atopic dermatitis in clarifying goals of treatment and developing and modifying treatment plan


Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use only. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site

Activity Information

Target Audience
The target audience for this educational activity was nurse practitioners and physician assistants who specialize in dermatology. Dermatologists and other clinicians who are members of the healthcare team providing care for patients with psoriasis/PsAand AD also benefited from participation in this activity.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.25 AMA PRA Category Credits™. Physician should claim only the credit commensurate with the extent of their participation in the activity.

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.17 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

This activity was approved for 1.17 contact hour(s) of continuing education (which includes 0.70 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043692. This activity was planning in accordance with AANP Accreditation Standards and Policies.

CME Content Review
The views and opinions expressed in this activity were those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers.  The reviewers of this activity had no relevant financial relationships to disclose.

This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs or devices.

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.